Latest stories on FHTX
Foghorn Therapeutics reports Q3 EPS 80c, consensus (25c)
The Fly74 · bullishearnings
Foghorn Therapeutics GAAP EPS of $0.80, revenue of $83.5M
Seeking Alpha64 · neutralearnings
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
GlobeNewswire54 · neutralearnings
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
StockTitan50 · neutralearnings
Foghorn Therapeutics Inc. (FHTX) files 8-K
SEC 8-K50 · neutralgeneral
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
StockTitan52 · neutralproduct/pr
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
GlobeNewswire52 · neutralproduct/pr
Foghorn Therapeutics downgraded to In Line from Outperform at Evercore ISI
The Fly34 · bearishanalyst
Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure
Investing.com Analyst Ratings24 · bearishanalyst
Foghorn: Downgrade 'Sell' Eli Lilly Exit FHD-909 And Shift To Preclinical Assets
Seeking Alpha28 · bearishanalyst
Why is Foghorn Therapeutics stock plunging today?
Investing.com Markets34 · bearishgeneral
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
Stocktwits News28 · bearishanalyst
Foghorn extends losses as TD Cowen cuts on Lilly exit
Business Insider34 · bearishanalyst
Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal - qz.com
Quartz28 · bearishgeneral
Wedbush cuts Foghorn Therapeutics stock rating on drug setback
Investing.com Analyst Ratings34 · bearishanalyst
Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt
Investing.com Analyst Ratings32 · bearishanalyst
Guggenheim cuts Foghorn Therapeutics price target on drug setback
Investing.com Analyst Ratings34 · bearishanalyst
Wedbush downgrades Foghorn on end of Lilly collaboration
The Fly34 · bearishanalyst
Foghorn Therapeutics price target lowered to $5 from $12 at Guggenheim
The Fly28 · bearishanalyst
Foghorn Therapeutics downgraded to Neutral from Outperform at Wedbush
The Fly46 · neutralanalyst
Foghorn Therapeutics price target lowered to $5 from $13 at H.C. Wainwright
The Fly28 · bearishanalyst
Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt
Investing.com Analyst Ratings34 · bearishanalyst
Foghorn Therapeutics downgraded to Neutral from Buy at BTIG
The Fly48 · neutralanalyst
Foghorn Therapeutics downgraded to Hold from Buy at TD Cowen
The Fly46 · neutralanalyst
Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation
Investing.com Analyst Ratings34 · bearishanalyst